<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">phkinetica</journal-id><journal-title-group><journal-title xml:lang="ru">Фармакокинетика и Фармакодинамика</journal-title><trans-title-group xml:lang="en"><trans-title>Pharmacokinetics and Pharmacodynamics</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2587-7836</issn><issn pub-type="epub">2686-8830</issn><publisher><publisher-name>ООО «Издательство ОКИ»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37489/2587-7836-2023-3-19-27</article-id><article-id custom-type="elpub" pub-id-type="custom">phkinetica-378</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ДОКЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ ФАРМАКОКИНЕТИКИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PRECLINICAL PHARMACOKINETIC STUDIES</subject></subj-group></article-categories><title-group><article-title>Сопоставление приёмов расчёта фармакокинетических параметров в исследованиях с дизайном «животное-точка»</article-title><trans-title-group xml:lang="en"><trans-title>Comparison of pharmacokinetic parameters calculation techniques in studies with animal-point design</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9690-1935</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Косман</surname><given-names>В. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Kosman</surname><given-names>V. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Косман Вера Михайловна - к. фарм. н., руководитель химико-аналитической лаборатории</p><p>Ленинградская обл., Всеволожский р-н, Кузьмолово</p></bio><bio xml:lang="en"><p>Vera M. Kosman - PhD, Cand. Sci. (Pharm), head of analytical laboratory</p><p>Leningrad oblast, Vsevolozhskiy district, Kuzmolovskiy t.s.</p></bio><email xlink:type="simple">kosman.vm@doclinika.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6292-8934</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Карлина</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Karlina</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Карлина Марина Валерьевна - к. б. н., руководитель отдела технологии, кинетики и анализа лекарственных средств</p><p>Ленинградская обл., Всеволожский р-н, Кузьмолово</p></bio><bio xml:lang="en"><p>Marina V. Karlina - PhD, Cand. Sci. (Biolog), head of department of technology, kinetics and analysis of drugs</p><p>Leningrad oblast, Vsevolozhskiy district, Kuzmolovskiy t.s.</p></bio><email xlink:type="simple">karlina.mv@doclinika.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3176-6386</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Макарова</surname><given-names>М. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Makarоva</surname><given-names>M. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Макарова Марина Николаевна - д. м. н., директор</p><p>Ленинградская обл., Всеволожский р-н, Кузьмолово</p></bio><bio xml:lang="en"><p>Marina N. Makarоva - Dr. Sci (Med.), director</p><p>Leningrad oblast, Vsevolozhskiy district, Kuzmolovskiy t.s.</p></bio><email xlink:type="simple">makarova.mn@doclinika.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2447-7888</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Макаров</surname><given-names>В. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Makarov</surname><given-names>V. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Макаров Валерий Геннадиевич - д. м. н., профессор, научный руководитель</p><p>Ленинградская обл., Всеволожский р-н, Кузьмолово</p></bio><bio xml:lang="en"><p>Valery G. Makarov - Dr. Sci (Med.), Professor, scientific supervisor</p><p>Leningrad oblast, Vsevolozhskiy district, Kuzmolovskiy t.s.</p></bio><email xlink:type="simple">makarov.vg@doclinika.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>АО «Научно-производственное объединение «ДОМ ФАРМАЦИИ»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research and manufacturing company “Home оf Pharmacy” JSC</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>02</day><month>11</month><year>2023</year></pub-date><volume>0</volume><issue>3</issue><fpage>19</fpage><lpage>27</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Косман В.М., Карлина М.В., Макарова М.Н., Макаров В.Г., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Косман В.М., Карлина М.В., Макарова М.Н., Макаров В.Г.</copyright-holder><copyright-holder xml:lang="en">Kosman V.M., Karlina M.V., Makarоva M.N., Makarov V.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmacokinetica.ru/jour/article/view/378">https://www.pharmacokinetica.ru/jour/article/view/378</self-uri><abstract><p>При исследовании фармакокинетики (ФК) лекарственных средств с применением мелких лабораторных животных, прежде всего грызунов, часто используют дизайн эксперимента «животное-точка», предполагающий отбор биологического материала после эвтаназии животного. Актуальным является вопрос обработки экспериментальных данных и способ расчёта ФК параметров, в ситуации, когда все значения концентраций получены от разных особей.</p><sec><title>Цель исследования</title><p>Цель исследования. Сопоставление приёмов расчёта фармакокинетических параметров в исследованиях фармакокинетики с дизайном «животное-точка».</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Для ряда исследований, проведённых нами ранее с использованием в качестве тест-систем самцов аутбредных крыс, был выполнен ретроспективный анализ данных и расчёт ФК параметров тремя различными способами: по средним значениям концентраций на каждой временной точке (способ 1): по данным, полученным для животных с одинаковыми порядковыми номерами в подгруппах, соответствующих временным точкам (способ 2); с применением ресемплинга, основанного на моделировании индивидуальных ФК-профилей (способ 3). Параметры фармакокинетики (максимальная концентрация — Сmax, время достижения максимальной концентрации — Тmax, площадь под кривой «концентрация—время» — AUC0–t, среднее время пребывания в организме — MRT, период полувыведения — T1/2) рассчитаны внемодельным методом статистических моментов с использованием валидированного приложения PKSolver для Microsoft Oﬃce Excel.</p></sec><sec><title>Результаты</title><p>Результаты. Сопоставление полученных результатов не позволило выявить какие-либо закономерности и предпочтения применения того или иного способа расчёта ФК параметров в зависимости от исследованных препаратов, пути и кратности введения. Для всех оценённых ФК параметров (Сmax, Тmax, AUC0–t, MRT, T1/2) получены близкие значения и/или интервалы, что свидетельствовало о корректности применения рассмотренных способов расчёта.</p></sec><sec><title>Заключение</title><p>Заключение. На основании сопоставления преимуществ и недостатков рассматриваемых способов расчёта, показано, что оптимально применение способа 2, являющегося частным случаем ресеплинга (способа 3) с минимальным количеством репликаций. Акцентирование использованного способа расчёта ФК параметров при описании методологии исследований важно для совершенствования их качества.</p></sec></abstract><trans-abstract xml:lang="en"><p>In pharmacokinetics (PK) studies of medicinal products with small laboratory animals models, primarily rodents, the design of the animal-point experiment is often used, involves the selection of biological material after euthanasia of the animal. The question of experimental data processing and the PK parameters calculation method in a situation where all concentration values  are obtained from diﬀerent individuals is relevant.</p><sec><title>Purpose of the study</title><p>Purpose of the study. Comparison of pharmacokinetic parameters calculation methods in studies with the animal-point design.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. For a number of previously conducted studies with male outbred rats test systems, a retrospective data analysis was performed and PK parameters were calculated in three diﬀerent ways: from the average concentration values at each time point (method 1): from data obtained for animals with the same sequence numbers in subgroups corresponding to time points (method 2); using resempling based on modeling of individual PK proﬁles (method 3). Pharmacokinetic parameters (maximum concentration — Cmax, time to reach maximum concentration — Tmax, area under the curve "concentration-time" — AUC0-t, average time to stay in the body — MRT, half-life — T1/2) were calculated by non-compartment method of statistical moments using the validated PKSolver application for Microsoft Oﬃce Excel.</p></sec><sec><title>Results</title><p>Results. The comparison of the obtained results did not reveal any patterns and preferences for the use of a particular method of calculating PK parameters depending on the studied drugs, route and administration way. For all evaluated PK parameters (Cmax, Tmax, AUC0-t, MRT, T1/2), similar values and/or intervals were obtained, which indicated the correctness of all considered calculation methods.</p></sec><sec><title>Conclusion</title><p>Conclusion. Based on advantages and disadvantages of the calculation methods comparison it is shown that it is optimal to use method 2, which is a special case of reception (method 3) with a minimum number of replications. It is important to emphasis the method of PK parameters calculation when describing the methodology of studies to improve their quality.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>фармакокинетика</kwd><kwd>крысы</kwd><kwd>дизайн животное на временную точку</kwd><kwd>расчёт параметров</kwd></kwd-group><kwd-group xml:lang="en"><kwd>pharmacokinetics</kwd><kwd>rats</kwd><kwd>animal per time point design</kwd><kwd>parameters calculation</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Valic MS, Halim M, Schimmer P, Zheng G. Guidelines for the experimental design of pharmacokinetic studies with nanomaterials in preclinical animal models. J Control Release. 2020 Jul 10;323:83–101. DOI: 10.1016/j.jconrel.2020.04.002.</mixed-citation><mixed-citation xml:lang="en">Valic MS, Halim M, Schimmer P, Zheng G. Guidelines for the experimental design of pharmacokinetic studies with nanomaterials in preclinical animal models. J Control Release. 2020 Jul 10;323:83–101. DOI: 10.1016/j.jconrel.2020.04.002.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Joyce AP, Wang M, Lawrence-Henderson R, et al. One mouse, one pharmacokinetic profile: quantitative whole blood serial sampling for biotherapeutics. Pharm Res. 2014 Jul;31(7):1823–1833. DOI: 10.1007/s11095-013-1286-y.</mixed-citation><mixed-citation xml:lang="en">Joyce AP, Wang M, Lawrence-Henderson R, et al. One mouse, one pharmacokinetic profile: quantitative whole blood serial sampling for biotherapeutics. Pharm Res. 2014 Jul;31(7):1823–1833. DOI: 10.1007/s11095-013-1286-y.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Liu L, Cao B, Aa J, et al. Prediction of the pharmacokinetic parameters of triptolide in rats based on endogenous molecules in pre-dose baseline serum. PLoS One. 2012;7(8):e43389. DOI: 10.1371/journal.pone.0043389.</mixed-citation><mixed-citation xml:lang="en">Liu L, Cao B, Aa J, et al. Prediction of the pharmacokinetic parameters of triptolide in rats based on endogenous molecules in pre-dose baseline serum. PLoS One. 2012;7(8):e43389. DOI: 10.1371/journal.pone.0043389.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Raje AA, Mahajan V, Pathade VV, et al. Capillary microsampling in mice: effective way to move from sparse sampling to serial sampling in pharmacokinetics profiling. Xenobiotica. 2020 Jun;50(6):663–669. DOI: 10.1080/00498254.2019.1683259.</mixed-citation><mixed-citation xml:lang="en">Raje AA, Mahajan V, Pathade VV, et al. Capillary microsampling in mice: effective way to move from sparse sampling to serial sampling in pharmacokinetics profiling. Xenobiotica. 2020 Jun;50(6):663–669. DOI: 10.1080/00498254.2019.1683259.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Руководство по проведению доклинических исследований лекарственных средств. Часть первая. / Миронов А. Н. М.: Гриф и К, 2012. 944 с.</mixed-citation><mixed-citation xml:lang="en">Rukovodstvo po provedeniyu doklinicheskih issledovanij lekarstvennyh sredstv. CHast' pervaya.  Mironov AN Moscow: Grif i K, 2012. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Косман В.М., Карлина М.В. Ретроспективная оценка вариабельности фармакокинетических параметров в зависимости от биологического вида и числа особей в экспериментальной группе. Лабораторные животные для научных исследований. 2023; 1. DOI: 10.57034/2618723X-2023-01-06.</mixed-citation><mixed-citation xml:lang="en">Kosman VM, Karlina MV. Retrospective of pharmacokinetic parameters variability in dependence on biological species and number of individuals in the experimental group. Laboratory Animals for Science. 2023; 1. (In Russ). DOI: 10.57034/2618723X-2023-01-06.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Gabrielsson J, Weiner D. Non-compartmental Analysis. In: Methods in Molecular Biology (Clifton, N.J.). Methods Mol Biol. 2012;(929):377–389. DOI:10.1007/978-1-62703-050-2_16.</mixed-citation><mixed-citation xml:lang="en">Gabrielsson J, Weiner D. Non-compartmental Analysis. In: Methods in Molecular Biology (Clifton, N.J.). Methods Mol Biol. 2012;(929):377–389. DOI:10.1007/978-1-62703-050-2_16.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Мирошниченко И.И., Симонов А.Н., Кузьмин И.И., Платова А.И. Анализ рассеянных данных в фармакокинетических исследованиях. Фармакокинетика и Фармакодинамика. 2020;(2):28–33.</mixed-citation><mixed-citation xml:lang="en">Miroshnichenko II, Simonov AN, Kuzmin II, Platova AI. Analysis of sparse data in pharmacokinetic studies. Pharmacokinetics and Pharmacodynamics. 2020;(2):28–33. (In Russ). DOI: 10.37489/2587-7836-2020-2-28-33.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">van Bree J, Nedelman J, Steimer J-L, et al. Application of Sparse Sampling Approaches in Rodent Toxicokinetics: A Prospective View. Drug Information Journal. 1994;28(1):263–279. DOI: 10.1177/009286159402800134</mixed-citation><mixed-citation xml:lang="en">van Bree J, Nedelman J, Steimer J-L, et al. Application of Sparse Sampling Approaches in Rodent Toxicokinetics: A Prospective View. Drug Information Journal. 1994;28(1):263–279. DOI: 10.1177/009286159402800134</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Wang T, Baron K, Zhong W, et al. Bayesian approach to estimate AUC, partition coefficient and drug targeting index for studies with serial sacrifice design. Pharm Res. 2014 Mar;31(3):649–659. DOI: 10.1007/s11095-013-1187-0.</mixed-citation><mixed-citation xml:lang="en">Wang T, Baron K, Zhong W, et al. Bayesian approach to estimate AUC, partition coefficient and drug targeting index for studies with serial sacrifice design. Pharm Res. 2014 Mar;31(3):649–659. DOI: 10.1007/s11095-013-1187-0.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Mahmood I. Naive pooled-data approach for pharmacokinetic studies in pediatrics with a very small sample size. Am J Ther. 2014 Jul-Aug;21(4):269–274. DOI: 10.1097/MJT.0b013e31824ddee3.</mixed-citation><mixed-citation xml:lang="en">Mahmood I. Naive pooled-data approach for pharmacokinetic studies in  pediatrics  with  a  very  small  sample  size.  Am  J  Ther.  2014  Jul-Aug;21(4):269–274. DOI: 10.1097/MJT.0b013e31824ddee3.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Chu HM, Ette EI. A random sampling approach for robust estimation of tissue-to-plasma ratio from extremely sparse data. AAPS J. 2005 Sep 2; 7(1):E249–58. DOI: 10.1208/aapsj070124.</mixed-citation><mixed-citation xml:lang="en">Chu HM, Ette EI. A random sampling approach for robust estimation of tissue-to-plasma ratio from extremely sparse data. AAPS J. 2005 Sep 2; 7(1):E249–58. DOI: 10.1208/aapsj070124.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Pozharitskaya ON, Shikov AN, Faustova NM, et al. Pharmacokinetic and Tissue Distribution of Fucoidan from Fucus vesiculosus after Oral Administration to Rats. Mar Drugs. 2018 Apr 18;16(4):132. DOI: 10.3390/md16040132.</mixed-citation><mixed-citation xml:lang="en">Pozharitskaya ON, Shikov AN, Faustova NM, et al. Pharmacokinetic and Tissue Distribution of Fucoidan from Fucus vesiculosus after Oral Administration to Rats. Mar Drugs. 2018 Apr 18;16(4):132. DOI: 10.3390/md16040132.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Shikov AN, Pozharitskaya ON, Faustova NM, et al. Pharmacokinetic Study of Bioactive Glycopeptide from Strongylocentrotus droebachiensis After Intranasal Administration to Rats Using Biomarker Approach. Mar Drugs. 2019 Oct 11;17(10):577. DOI: 10.3390/md17100577.</mixed-citation><mixed-citation xml:lang="en">Shikov AN, Pozharitskaya ON, Faustova NM, et al. Pharmacokinetic Study of Bioactive Glycopeptide from Strongylocentrotus droebachiensis After Intranasal Administration to Rats Using Biomarker Approach. Mar Drugs. 2019 Oct 11;17(10):577. DOI: 10.3390/md17100577.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Косман В.М., Демченко Д.В., Джайн (Корсакова) Е.А. и др. Исследование фармакокинетики оригинального лекарственного средства для лечения ВИЧ-1 инфекции. Фармация. 2021;70(4):48–56. DOI: 10/29296/25419218-2021-04-08.</mixed-citation><mixed-citation xml:lang="en">Kosman VM, Demchenko DV, Jain (Korsakova) EA, et al. Investigation of the pharmacokinetics of an original drug for the treatment of HIV-1 infection. Pharmacy. 2021;70(4):48–56. (In Russ). DOI: 10/29296/25419218-2021-04-08.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Y, Huo M, Zhou J, Xie S. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed. 2010 Sep;99(3):306–314. DOI: 10.1016/j.cmpb.2010.01.007.</mixed-citation><mixed-citation xml:lang="en">Zhang Y, Huo M, Zhou J, Xie S. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed. 2010 Sep;99(3):306–314. DOI: 10.1016/j.cmpb.2010.01.007.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Beconi MG, Howland D, Park L, et al. Pharmacokinetics of memantine in rats and mice. PLoS Curr. 2011 Dec 15;3:RRN1291. DOI: 10.1371/currents.RRN1291.</mixed-citation><mixed-citation xml:lang="en">Beconi MG, Howland D, Park L, et al. Pharmacokinetics of memantine in rats and mice. PLoS Curr. 2011 Dec 15;3:RRN1291. DOI: 10.1371/currents.RRN1291.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Жердев В.П., Бойко С.С., Блынская Е.В. и др. Доклиническое изучение фармакокинетики нового анксиолитика дипетидной структуры ГБ-115. Фармакокинетика и Фармакодинамика. 2015;(1):52–59.</mixed-citation><mixed-citation xml:lang="en">Zherdev VP, Boyko SS, Blynskaya EV, et al. Preclinical study the pharmacokinetics new anxiolytic drug of dipeptide structure GB-115. Pharmacokinetics and Pharmacodynamics. 2015;(1):52–59. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Жердев В.П., Колыванов Г.Б., Литвин А.А. и др. Сравнительное изучение фармакокинетики метаболита тропоксина у различных видов животных и человека. Фармакокинетика и Фармакодинамика. 2017;(2):30–34.</mixed-citation><mixed-citation xml:lang="en">Zherdev VP, Kolyvanov GB, Litvin AA, et al. Pharmacokinetic comparative study of tropoxine metabolite in miscellaneous animal species and humans. Pharmacokinetics and Pharmacodynamics. 2017;(2):30–34. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Раскин С.Ю., Колыванов Г.Б., Литвин А.А. и др. Фармакокинетика дипептидного анксиолитика ГБ-115 после перорального введения у различных видов животных и человека. Фармакокинетика и Фармакодинамика. 2017;(3):20–25.</mixed-citation><mixed-citation xml:lang="en">Raskin SYu, Kolyvanov GB, Litvin AA, et al. Pharmacokinetics of dipeptide anxiolytic GB-115 after oral administration in  different  animals  species  and  humans.  Pharmacokinetics  and Pharmacodynamics. 2017;(3):20–25. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Ковалёв Г.И., Золотарёв Ю.А., Дадаян А.К. и др. Изучение фармакокинетики [3Н]-циклопролилглицина в крови крыс. Фармакокинетика и Фармакодинамика. 2018;(3):48–56. DOI: 10.24411/2587-7836-2018-10024.</mixed-citation><mixed-citation xml:lang="en">Kovalev GI, Zolotarev YuA, Dadayan AK, et al. The Study of [3H]-Cycloprolylglycine Pharmacokinetics in Rat Blood. Pharmacokinetics and Pharmacodynamics. 2018;(3):48–56. (In Russ). DOI: 10.24411/2587-7836-2018-10024.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Ноздрин В. И., Пьявченко Г. А., Иванова М. Е., Гузев К. С., Кузнецов С. Л. Изучение некоторых параметров фармакокинетики фенола, входящего в состав пасты с антисептиком-стимулятором Дорогова 3 фракции. Разработка и регистрация лекарственных средств. 2019;8(3):57–61. DOI: 10.33380/2305-2066-2019-8-3-57-61.</mixed-citation><mixed-citation xml:lang="en">Nozdrin VI, Piavchenko GA, Ivanova ME, Guzev KS, Kuznetsov SL. Evaluation of pharmacokinetical parameters of phenol, a component of Dorogov's antiseptic-stimulator 3 fraction paste. Drug development &amp; registration. 2019; 8(3): 57–61. (In Russ). DOI: 10.33380/2305-2066-2019-8-3-57-61.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Борозденко Д.А., Ляхман Д.Н., Голубев Я.В. и др. Изучение фармакокинетики и нейропротекторной активности нового производного 4-фенилпирролидинона-2 в модели ишемического инсульта на животных. Вестник РГМУ. 2020;(1):51–58. DOI: 10.24075/vrgmu.2020.010.</mixed-citation><mixed-citation xml:lang="en">Borozdenko DA, Lyakhmun DN, Golubev YV, et al. Study of the new 4-phenylpyrrolidinone-2 derivative pharmacokinetics and neuroprotective effect in the ischemic stroke animal model. Bulletin of RSMU. 2020;(1):49–56.]. DOI: 10.24075/vrgmu.2020.010.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Altman DG, Bland JM. How to randomize. BMJ. 1999;319(7211): 703–704. DOI: 10.1136/bmj.319.7211.703.</mixed-citation><mixed-citation xml:lang="en">Altman DG, Bland JM. How to randomize. BMJ. 1999;319(7211): 703–704. DOI: 10.1136/bmj.319.7211.703.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Bland J.M. An Introduction to Medical Statistics. 3rd edition. New York: Oxford University Press, 2000. 422 р.</mixed-citation><mixed-citation xml:lang="en">Bland J.M. An Introduction to Medical Statistics. 3rd edition. New York: Oxford University Press, 2000. 422 р.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Рекомендация Коллегии Евразийской экономической комиссии от 22.12.2020 N 33 «О Руководстве по изучению токсикокинетики и оценке системного воздействия в токсикологических исследованиях лекарственных препаратов». URL: https://www.alta.ru/tamdoc/20rk0033/</mixed-citation><mixed-citation xml:lang="en">Recommendation of the Board of the Eurasian Economic Commission dated 22.12.2020 N 33 «O Rukovodstve po izucheniyu toksikokinetiki i ocenke sistemnogo vozdejstviya v toksikologicheskih issledovaniyah lekarstvennyh preparatov». (In Russ). URL: https://www.alta.ru/tamdoc/20rk0033/</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Lee SY. Bayesian Nonlinear Models for Repeated Measurement Data: An Overview, Implementation, and Applications. Mathematics. 2022;10:898. DOI: 10.3390/math10060898.</mixed-citation><mixed-citation xml:lang="en">Lee SY. Bayesian Nonlinear Models for Repeated Measurement Data: An Overview, Implementation, and Applications. Mathematics. 2022;10:898. DOI: 10.3390/math10060898.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Быков В.В., Леонов К.А., Серебров В.Ю., Удут В.В. Фармакокинетика циркулирующего пула антиагреганта индолинонового ряда. Journal of Siberian Medical Sciences. 2019;(3):44–51. DOI: 10.31549/2542-1174-2019-3-44-51.</mixed-citation><mixed-citation xml:lang="en">Bykov VV, Leonov KA, Serebrov VYu, Udut VV. Pharmacokinetics of an antiplatelet drug of indolinone series in the bloodstream. Journal of Siberian Medical Sciences. 2019;3:44–51. (In Russ). DOI: 10.31549/2542-1174-2019-3-44-51.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Быкова А.В., Быков В.В., Мотов В.С. и др. Фармакокинетические параметры сложноэфирного производного индометацина. Journal of Siberian Medical Sciences. 2020;(3):17–26. DOI: 10.31549/2542-1174-2020-3-17-26.</mixed-citation><mixed-citation xml:lang="en">Bykova AV, Bykov VV, Motov VS, et al. Pharmacokinetic parameters of an ester derivative of indomethacin. Journal of Siberian Medical Sciences. 2020;(3):17–26. (In Russ). DOI: 10.31549/2542-1174-2020-3-17-26.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Решение Совета ЕЭК №81 «Об утверждении правил надлежащей лабораторной практики Евразийского экономического союза в сфере обращения лекарственных средств» от 03.11.2016 г. URL: https://www.alta.ru/tamdoc/16sr0081/</mixed-citation><mixed-citation xml:lang="en">Decision of the EEC Council No. 81 «Ob utverzhdenii pravil nadlezhashchej laboratornoj praktiki Evrazijskogo ekonomicheskogo soyuza v sfere obrashcheniya lekarstvennyh sredstv»  ot  03.11.2016.  (In  Russ).  URL:  https://www.alta.ru/tamdoc/16sr0081/</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Межгосударственный стандарт ГОСТ 33044–2014 «Принципы надлежащей лабораторной практики».URL: https://docs.cntd.ru/document/1200115791.</mixed-citation><mixed-citation xml:lang="en">Interstate standard GOST 33044-2014 «Principy nadlezhashchej laboratornoj praktiki». (In Russ). URL: https://docs.cntd.ru/document/1200115791</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
